Ho et al reported that improved renal function associated with high-dose atorvastatin reduced hospitalization for heart failure (HF) in the Treating to New Targets (TNT) trial. In the Greek Atorvastatin and Coronary-Heart-Disease Evaluation (GREACE) study, 63 of 800 patients treated to low-density lipoprotein cholesterol target with atorvastatin had HF at baseline. Among these patients, 10 were hospitalized for HF during 3-year follow-up. They had a 2% increase in estimated glomerular filtration rate at 1 year compared with a 7.5% increase in those not hospitalized (p = 0.002). Among the 800 patients receiving usual care, 55 had HF at baseline, and of those, 21 patients were hospitalized for HF during 3-year follow-up. These patients had a 5% decrease in estimated glomerular filtration rate at 1 year compared with a 0.8% increase in those not hospitalized (p = 0.001). The patients treated to low-density lipoprotein cholesterol target group had lower risk for hospitalization for HF (p = 0.003). These findings support those from TNT.